Application of triazole derivative LD-18 in preparation of anti-type 2 diabetes medicine taking PPAR gamma and alpha-glucosidase as targets
By developing the triazole trozolate derivative LD-18, combining PPARγ and inhibiting α-glucosidase, the side effects of existing drugs were solved, and effective glycemic lowering effect and safety in db/db model mice were achieved.
Patent Information
- Application Number
- CN202311523904.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-11-15
- Publication Date
- 2024-11-15
AI Technical Summary
Existing PPARγ target drugs lead to side effects such as weight gain and liver enlargement, while α-glucosidase inhibitors are accompanied by side effects such as flatulence, bloating, diarrhea and nephrotoxicity, making it difficult to find one that can effectively reduce blood sugar and be safe. Type 2 diabetes medication.
Developed a triazole kojic acid derivative LD-18. Through high-throughput virtual screening, it was found that it can bind to PPARγ, inhibit α-glucosidase activity, and showed a glycemic effect in db/db model mice. No side effects of weight gain.
As a dual-target regulator, LD-18 has effectively reduced fasting blood sugar without side effects, avoided side effects of traditional drugs, and showed a new, safe and efficient lowering effect of sugar.
Smart Images

Figure CN118948844A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of pharmaceutical technology and relates to N-(5-((1-((5-hydroxy-4-oxo-4H-pyran-2-yl)methyl)-1H-1,2,3-triazol-4-yl)methyl)thio)-1,3,4-thiadiazole-2-yl)-4-bromophenylacetamide (LD-18) ( Figure 1 ) in the preparation of anti-type 2 diabetes drugs targeting PPARγ and α-glucosidase. Background Art
[0002] Diabetes is a global metabolic chronic disease characterized by high blood sugar. According to the 2021 Global Diabetes Atlas (10th edition) recently released by the World Diabetes Federation (IDF), about 537 million adults (20-79 years old) suffer from diabetes in 2021, accounting for about 10.5% of the global population. It is estimated that by 2030, the number of patients will reach 643 million (12.2%), and will rise to 783 million by 2045. At present, the number of diabetes patients in my country has reached 140 million, of which type 2 diabetes (T2DM) accounts for more than 90%, which has become a major disease second only to cancer and cardiovascular and cerebrovascular diseases, seriously threatening people's lives and health.
[0003] Peroxisome proliferator-activated receptors (PPARs) are ligand-activated receptors in the nuclear hormone receptor family and are key regulators of glucose and lipid metabolism and insulin sensitivity. Many studies have shown that PPARγ mediates a variety of important physiological functions, such as lipogenesis, blood glucose and lipid metabolism, insulin sensitivity, and adipocyte hormone secretion. Thiazolidinediones (TZDs) developed with PPARγ as a target have a significant hypoglycemic effect in vivo, but because they also activate lipogenesis-related signaling pathways while regulating the PPARγ downstream hypoglycemic signaling pathway, they cause side effects such as weight gain and liver enlargement, which has led to the gradual withdrawal of this type of drug from the market. Therefore, the development of a new, safe, and highly effective hypoglycemic PPARγ selective regulator that can retain insulin sensitization and reduce the side effects caused by full activation of PPARγ has become an urgent need in the medical community.
[0004] α-Glucosidase is mainly located on the brush border of the small intestinal mucosal cells. It is a key enzyme for the digestion of carbohydrates in the body. It promotes the decomposition of carbohydrates such as starch, sucrose, and maltose in intestinal food into monosaccharides, which are absorbed by the epithelial cells of the upper small intestine and enter the blood circulation, leading to increased blood sugar after meals. α-Glucosidase inhibitors delay the absorption of glucose by inhibiting the digestive enzymes on the brush border of the small intestinal mucosa. Currently, the α-glucosidase inhibitors on the market include acarbose, voglibose, and miglitol. Although the above-mentioned drugs can effectively lower the blood sugar of patients with type 2 diabetes and can also reduce the complications of type 2 diabetes to a certain extent, the above-mentioned drugs are also accompanied by side effects such as intestinal flatulence, abdominal distension, diarrhea, indigestion, and nephrotoxicity, which seriously restrict the use of such drugs.
[0005] In summary, it is urgent to find new, safe and effective anti-type 2 diabetes drugs targeting PPARγ and α-glucosidase. Summary of the invention
[0006] The purpose of the present invention is to provide a selective regulator LD-18 targeting PPARγ and α-glucosidase dual targets for use in the preparation of anti-type 2 diabetes drugs.
[0007] The inventors used high-throughput virtual screening technology to find that the kojic acid triazole derivative LD-18 not only has a strong binding ability with PPARγ, but also can inhibit the activity of α-glucosidase to a certain extent. 50 The results of luciferase activity assay and adipocyte differentiation induction experiments showed that compared with the PPARγ full agonist rosiglitazone, LD-18 only weakly activated PPARγ and induced adipocyte differentiation. In db / db model mice, LD-18 showed a good hypoglycemic effect at a concentration of 5 mg / kg, and did not cause the side effect of weight gain in mice.
[0008] The first object of the present invention is to provide the use of LD-18 in preparing anti-type 2 diabetes drugs.
[0009] Preferably, the anti-diabetic drug is an anti-type 2 diabetes drug with PPARγ and α-glucosidase as dual targets.
[0010] The present invention also provides an anti-type 2 diabetes drug, which contains an effective amount of LD-18 as an active ingredient and a pharmaceutically acceptable carrier.
[0011] Preferably, the anti-diabetic drug is an anti-type 2 diabetes drug with PPARγ and α-glucosidase as dual targets.
[0012] The present invention discovered for the first time that LD-18 has a high-efficiency hypoglycemic effect with PPARγ and α-glucosidase as dual targets and has low toxic side effects, and can be developed as an anti-diabetic drug. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1 is the chemical formula of LD-18;
[0014] Figure 2 is the ability of LD-18 to bind to PPARγ, and the IC 50 1.7 μM;
[0015] Figure 3 The IC value of LD-18 for inhibiting α-glucosidase is 50 1.2 μM;
[0016] Figure 4 This is a result of the ability of LD-18 to activate PPARγ. Compared with the complete activation of PPARγ by rosiglitazone, LD-18 only weakly activates PPARγ;
[0017] Figure 5 The results of Oil Red O staining to detect the ability of LD-18 to induce adipocyte differentiation show that compared with rosiglitazone, the ability of LD-18 to induce adipocyte differentiation is weaker;
[0018] Figure 6 The hypoglycemic effect and body weight changes of LD-18 in db / db model mice. LD-18 can effectively reduce fasting blood sugar in diabetic model mice without causing weight gain; DETAILED DESCRIPTION
[0019] The following examples are provided to further illustrate the present invention, rather than to limit the present invention.
[0020] 1. TR-FRET assay to detect the binding ability of dicoumarol to PPARγ
[0021] 1) Dilute LD-18 to 1000μM with DMSO. DMSO is used as blank control and rosiglitazone is used as positive control drug; 2) Dilute 1000μM LD-18 solution to 2, 20, 200μM and other different concentrations with TR-FRET buffer solution; 3) Prepare 4×Fluormone TM Pan-PPAR Green solution (20nM) with TR-FRET buffer solution as solvent; 4) Prepare 4×Tb anti-GST antibody (20nM) and 4×PPARγ-LBD protein (2nM) with TR-FRET buffer solution as solvent; 5) Add 20μl of the solution prepared in step 2, 10μl of the solution prepared in step 3 and 10μl of the solution prepared in step 4 to 384-well plate respectively and shake for 6 hours; 6) Read on the microplate reader.
[0022] The experimental results are shown in Figure 2 The results showed that the IC of LD-18 binding to PPARγ 50 is 1.7μM.
[0023] 2. Detection of LD-18 and inhibition of α-glucosidase activity
[0024] 1) Dilute LD-18 to 1000 μM with DMSO. 1) DMSO was used as a blank control and acarbose as a positive control drug; 2) 1000 μM LD-18 solution was diluted again to different concentrations of 100, 50, 25 μM, etc. with PBS solution (0.05 mol / L, PH=6.8); 3) α-glucosidase (0.2 U / mL) was diluted with PBS solution (0.05 mol / L, PH=6.8); 4) pNPG (2.5 mM) was diluted with PBS solution (0.05 mol / L, PH=6.8); 5) 2 μl of the solution prepared in step 2, 20 μl of the solution prepared in step 3 and 118 μl PBS solution (0.05 mol / L, PH=6.8) were added to a 96-well plate respectively, and after reacting at 37°C for 15 min, 40 μL of sodium carbonate solution (0.2 mol / L) was added to terminate the reaction; 6) The reading was read on an ELISA reader (405 nm).
[0025] The experimental results are shown in Figure 3 The results showed that LD-18 inhibited α-glucosidase with an IC 50 is 1.2μM.
[0026] 3. Luciferase activity assay to detect the ability of LD-18 to activate PPARγ
[0027] Cos-7 cells purchased from ATCC were cultured in 10% FBS in antibiotic-free DMEM and placed in an incubator at 37°C and 5% CO2. After the cells entered the logarithmic growth phase, they were seeded in a 24-well plate. When the cell fusion was about 70%, plasmid co-transfection (50ng full-length hPPARγ, 100ng PPARγ, 5ng Renilla luciferase plasmid) was performed according to the operating instructions of lipofectamine2000 (Invitrogen). 1μM LD-18 was added to the transfected cells 24h later, with rosiglitazone (1μM) as the positive control and DMSO as the blank control. Luciferase activity was determined 24h later according to the operating instructions of Reporter luciferase assay kits (Promega), with 3 independent test wells set up for each group. The experimental results are shown in Figure 4 The results showed that LD-18 only weakly activated PPARγ, compared with rosiglitazone, which fully activated PPARγ.
[0028] 4. Oil red staining to detect the ability of LD-18 to induce adipocyte differentiation
[0029] 3T3-L1 preadipocytes purchased from ATCC were cultured in 10% FBS DMEM containing penicillin-streptomycin double antibodies and placed in an incubator at 37°C and 5% CO2. The cells were seeded in a culture plate and 2 days after they grew to confluence, 10% FBS DMEM induction solution containing 0.5mmol / L IBMX (3-isobutyl-1-methylxanthine), 1μmol / LDEX (dexamethasone), and 850nmol / L insulin were added. After 48h, it was replaced with 10% FBS high-glucose DMEM containing 850nmol / L insulin, and changed every 2 days. 1μM rosiglitazone was used as the positive control, DMSO was used as the blank control, and the test group was 1μM LD-18. After 6 days of differentiation, Oil Red O staining was performed, and photos were taken with a microscope (OLYMPUS), and the adipocyte differentiation rate was calculated. The experimental results are shown in Figure 5 The results showed that compared with rosiglitazone (Rosi) (adipocyte differentiation rate 61.25%), LD-18 had a weaker ability to induce adipocyte differentiation (adipocyte differentiation rate was only 15.06%).
[0030] 5. Hypoglycemic effect and body weight changes of LD-18 in db / db model mice
[0031] Six-week-old db / db model mice were purchased and randomly divided into groups. The intraperitoneal injection solvent group (Vehicle), LD-18 administration group (5mg / kg, 10mg / kg), PPARγ selective full agonist rosiglitazone (Rosi, 5mg / kg) and α-glucosidase inhibitor acarbose (Acar, 5mg / kg) were used as the control group. The drug was administered once a day, and the fasting blood glucose, fasting body weight and glucose tolerance level of mice in each experimental group were tested after three weeks of administration. The experimental results are shown in Figure 6 .
[0032] The results showed that LD-18 could significantly reduce the fasting blood glucose of mice ( Figure 6 .A), and did not cause a significant increase in the weight of the mice ( Figure 6 .B). After fasting for 16 hours, the fasting blood glucose value of mice was first measured as a benchmark (0min), and then glucose was injected intraperitoneally (iPGTT method) at a dose of 1g glucose / kg body weight. Blood glucose levels were measured at 30, 60, 90 and 120min after glucose injection. The results showed that LD-18 could also improve glucose tolerance to a certain extent, and showed a dose-dependent effect ( Figure 6 .CD).
[0033] The above experimental results show that (1) LD-18 in the present invention not only has a strong binding affinity to PPARγ, but also has an IC 50 The activity of α-glucosidase was inhibited to a certain extent. The IC 50 1.2μM. (2) LD-18 in the present invention not only exhibits a weak ability to activate PPARγ, but also weakly induces adipocyte differentiation. (3) LD-18 in the present invention can effectively reduce fasting blood glucose in diabetic model mice without causing weight gain.
[0034] In summary, LD-18, as a new type of PPARγ selective regulator and α-glucosidase, can not only exert the effect of lowering blood sugar, but also will not cause toxic side effects similar to thiazolidinediones.
Claims
1. Use of a triazole derivative N-(5-((1-((5-hydroxy-4-oxo-4H-pyran-2-yl)methyl)-1H-1,2,3-triazol-4-yl)methyl)thio)-1,3,4-thiadiazol-2-yl)-4-bromophenylacetamide (LD-18) in the preparation of an anti-type 2 diabetes drug targeting PPARγ and α-glucosidase.
